NCT02627963
Disease Type: Gastrointestinal
Status: Open
Trial Information
A Phase III, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride (AV-951) to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
This trial is available at:
Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact:
